Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Novel Delivery System for Acute Conditions: Milestone's lead product, etripamil, utilizes a proprietary nasal spray for rapid delivery, offering a non-invasive and convenient alternative to traditional intravenous or oral treatments for acute cardiovascular events like PSVT.
Empowerment Through Self-Administration: The investigational nature of etripamil allows for potential patient self-administration outside of a clinical setting, reducing the burden of emergency room visits and improving patient autonomy in managing acute episodes.
Addressing a Significant Unmet Need: The company focuses on addressing acute paroxysmal supraventricular tachycardia (PSVT), a condition where rapid, accessible, and effective treatment options outside of a hospital are highly valued by patients.
Risks
Clinical Trial Failure: Etripamil's ongoing or future clinical trials may not achieve their primary or secondary endpoints, demonstrate sufficient efficacy, or prove to be acceptably safe, leading to delays or abandonment of the product candidate.
Regulatory Approval Challenges: Even with positive clinical data, etripamil may fail to gain marketing approval from regulatory authorities such as the FDA, due to stringent review processes, requirements for additional data, or unexpected safety concerns.
Commercialization and Market Acceptance: If approved, etripamil's commercial success depends on market adoption by physicians and patients, adequate pricing and reimbursement by payers, and effective competition against existing and future treatments for PSVT.
Over a week ago
May 13, 5:30 PM
May 13, 7:21 AM
Apr 10, 8:02 AM
Apr 10, 5:33 AM
Apr 9, 4:30 PM
Mar 31, 8:02 AM
Mar 20, 7:15 AM
Mar 16, 8:16 AM
Feb 10, 8:20 AM
Feb 3, 8:23 AM
Jan 26, 8:09 AM
Jan 6, 8:17 AM
Dec 16, 6:45 AM
Dec 15, 10:07 AM
Dec 15, 10:04 AM
Dec 15, 9:47 AM
Dec 14, 11:26 AM
Dec 12, 6:06 PM
Nov 12, 7:16 AM
Nov 3, 8:21 AM
Sep 11, 5:25 AM
Aug 12, 7:18 AM
